Palisade Bio, Inc. PALI

Oral presentation to highlight early endoscopic improvement and evidence of PDE4 target engagement in fibrostenotic Crohn’s disease Three moderated posters to showcase gut-targeted exposure, favorable safety and tolerability, rapid clinical response in ulcerative colitis, and the development of a biomarker to predict treatment response Denver, CO, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company develop

Canadian clearance supports site activation and enrollment in the global study of once-daily oral PALI-2108 Primary efficacy results from approximately 204 patients with moderately to severely active ulcerative colitis expected in the second half of 2027 Denver, CO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic dis

Palisade Bio, Inc. Phase 2 ASCENTRA-CD clinical trial in patients with moderate to severe Crohn’s disease (CD) ASCENTRA-CD expected to enroll approximately 60 patients with moderate to severe Crohn’s disease First patient dosing targeted for Q1 2027; primary efficacy readout (Week 12 endoscopic response) targeted for Q1 2028 Phase 2 program builds on clinical experience in fibrostenotic Crohn’s disease demonstrating targeted tissue exposure, PDE4 target engagement and encouraging endoscopic acti

Presentation scheduled for September 23, 2026 at 1:00 PM ET Access the webcast here Denver, CO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic diseases, today announced that JD Finley, Chief Executive Officer, and Mitchell Jones, M.D., Ph.D., President and Chief Medical Officer, will participate in the Stifel 2026 V

Denver, CO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic diseases, today announced that members of management will participate in three healthcare investor conferences in September 2026. Wells Fargo 2026 Healthcare Conference Dates: September 8–10, 2026Location: Boston, MassachusettsFormat: Investor meetings Morga

Advancing a potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug specifically engineered for the treatment of inflammatory bowel disease (IBD) Enrollment of first patient for Phase 2 ASCENTRA-UC trial of PALI-2108 expected in the second half of 2026; primary efficacy results expected in the second half of 2027 IND for Phase 2 ASCENTRA-CD trial of PALI-2108 for the treatment of Crohn’s disease expected in the second half of 2026 Strong balance sheet expected to supp

Oppenheimer on Thursday initiated coverage of Palisade Bio Inc., saying the stock offers investors an attractive way to gain exposure to the fast-growing inflammatory bowel disease market. The company’s lead candidate, PALI-2108, is a once-daily oral PDE4 inhibitor prodrug designed...

Management to participate in investor meetings on July 14-15 in Boston Denver, CO, July 10, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation oral PDE4 inhibitor prodrugs for inflammatory bowel disease, today announced that JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, President & Chief Medical Officer, will participate in the Leerink Partners Therapeutics Forum, taking pla

Palisades Goldcorp Ltd. (TSXV: PALI) ("Palisades" or the "Company") is pleased to announce the appointment of Colonel Douglas A. Macgregor, Ph.D. (Ret.) to its Board of Directors. Colonel Macgregor is a decorated combat veteran with 28 years of service in the United States Army, a published author, a Ph.D. in international relations, and a former Senior Advisor to the U.S. Secretary of Defense. His appointment reflects Palisades' commitment to assembling a world-class board with deep expertise i

Palisade Bio received clearance from the U.S. Food and Drug Administration for its Investigational New Drug application for PALI-2108, an ulcerative colitis treatment.

ASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative colitis across North America and Europe First patient enrollment anticipated in the second half of 2026; primary efficacy results expected in the second half of 2027 IND clearance marks a major development milestone for PALI-2108 and supports continued advancement of the Company’s inflammatory bowel disease portfolio Denver, CO, June 29, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Pal

Board strengthened with extensive biotechnology leadership, strategic transactions and capital markets expertise Company continues to build on PALI-2108 clinical progress as it advances toward Phase 2 development and additional key milestones Denver, CO, June 11, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to

Presentation to highlight fibrostenotic Crohn’s disease biology and the potential of a locally bioactivated PDE4 inhibitor prodrug approach Denver, CO, June 09, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced Mitchell Jones, MD, PhD, President and Chief Medical Offi

Management presentation to take place on Thursday, June 4th at 3:45 PM ET Register for the webcast here Denver, CO, May 27, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, President & Chief Medical Off